NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Published 2016 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 27, Issue suppl_6, Pages -

Publisher

Oxford University Press (OUP)

Online

2017-02-04

DOI

10.1093/annonc/mdw435.39

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Become a Peeref-certified reviewer